Description:
GEM Hemochron 100 System by Accriva Diagnostics Inc.
The GEM Hemochron 100 System is a state-of-the-art medical device developed by Accriva Diagnostics Inc. It includes the GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+), the GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR), and directCHECK Whole Blood Control units at Levels 1 and 2 for both ACT+ and ACT-LR.
Its primary usage lies within the realm of coagulation testing - a critical aspect of healthcare that measures how efficiently the blood forms clots to prevent excessive bleeding. This device has shown to be exceptionally beneficial in routine monitoring for anticoagulant therapies, or during sensitive surgical procedures where immediate results are required for effective decision making. It offers both ACT+ and ACT-LR tests, allowing medical professionals a valuable range to select from based on their specific requirements.
Further enhancing its usefulness, the system comes with directCHECK Whole Blood Control units. These tools provide reliable assurance, allowing professionals to confirm test accuracy and precision. This feature enables the system's consistent usage, upholding the highest standards of patient safety and care.
Accriva Diagnostics Inc. developed the GEM Hemochron 100 System with a keen understanding of the vital role rapid, accurate clotting time results play in clinical decision-making processes. It is carefully designed to aid physicians and healthcare professionals in providing optimal patient care, improving outcomes in a range of situations from routine anticoagulant management to critical and emergency scenarios.
How It Works:
Overview
The GEM Hemochron 100 System, inclusive of the GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+), GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR), directCHECK ACT+ Whole Blood Control Levels 1 and 2, and directCHECK ACT-LR Whole Blood Control Levels 1 and 2 devices, is an innovative tool in the field of clinical hematology and
cardiology.
Functionality
Activated Clotting Time (ACT)
One of the critical tests the GEM Hemochron 100 System performs is the
Activated Clotting Time (ACT). ACT is a major diagnostic measure in monitoring anticoagulation during procedures that require high-dose heparin therapy, such as
cardiopulmonary bypass surgery.
ACT+ and ACT-LR tests
The GEM Hemochron 100 ACT+ and ACT-LR tests are designed to be an integral part of the GEM Hemochron 100 System. These tests help assess the coagulation cascade efficiency by testing the whole blood clotting time. They also assist in determining the appropriate heparin dosage.
Whole Blood Controls
The directCHECK ACT+ and ACT-LR Whole Blood Control have been designed to monitor the performance and precision of the GEM Hemochron 100 System. The level 1 and 2 controls ensure that the device's operations are under standardized limits, allowing for patient safety and minimum margin of error.
Operation
The GEM Hemochron 100 system utilizes microprocessor technology to provide rapid, accurate, and precise test results. This handheld device houses an internal timer that begins once a
blood sample is applied to the test cartridge. An audible alert and digital display inform the user when the clotting pathway is blocked, ensuring accurate results.
With its advanced design and exceptional versatility, the GEM Hemochron 100 System contributes significantly to cardiovascular diagnosis and therapeutic decision-making. It stands as a vital tool in predicting, monitoring, and managing the risk of bleeding and clotting complications in cardiac procedures.